

# Chronic Neuropathic Pain (CNP) - Pipeline Insight, 2019

<https://marketpublishers.com/r/C7F29E6AC38EN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: C7F29E6AC38EN

## Abstracts

This report can be delivered to the clients within 24 Hours

"Chronic Neuropathic Pain (CNP) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Neuropathic Pain pipeline landscape is provided which includes the disease overview and Chronic Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Chronic Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Chronic Neuropathic Pain Understanding

According to the International Association for the Study of Pain (IASP), chronic neuropathic pain is chronic pain caused by a lesion or disease of the somatosensory nervous system. The pain may be spontaneous or evoked, as an increased response to a painful stimulus (hyper-algesia) or a painful response to a normally non-painful stimulus (allodynia). The diagnosis of chronic neuropathic pain requires a history of nervous system injury or disease and a neuro-anatomically plausible distribution of the pain. Negative (e.g., decreased or loss of sensation) and positive sensory symptoms or signs (e.g., allodynia or hyperalgesia) indicating the involvement of the somatosensory nervous system must be compatible with the innervation territory of the affected nervous structure. CNP is a major factor contributing to the global burden of disease. Its

prevalence ranges between 6.9% and 10% of the general population. Chronic pain is defined as pain that lasts or recurs for more than three months. With CNP, the nerve fibers themselves might be damaged, dysfunctional, or injured. These damaged nerve fibers send incorrect signals to other pain centers. The impact of a nerve fiber injury includes a change in nerve function both at the site of injury and areas around the injury. Chronic manifestations commence with subtle pain and develop gradually.

### Chronic Neuropathic Pain Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Chronic Neuropathic Pain targeted therapeutics development with respective active and dormant or discontinued projects. Chronic Neuropathic Pain pipeline report covers 18+ companies. Some of the key players include, Algiax Pharmaceuticals (AP-325), Syntrix Biosystems (Desmetramadol), Centrexion Therapeutics (CNTX 2022) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

### Chronic Neuropathic Pain Analytical Perspective by DelveInsight

#### In-depth Chronic Neuropathic Pain Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

#### Chronic Neuropathic Pain Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this

indication.

## **Scope of the report**

The Chronic Neuropathic Pain report provides an overview of therapeutic pipeline activity for Chronic Neuropathic Pain across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Chronic Neuropathic Pain therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Chronic Neuropathic Pain Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Chronic Neuropathic Pain

## **Reasons to Buy**

Establish a comprehensive understanding of the current pipeline scenario across Chronic Neuropathic Pain to formulate effective R&D strategies

Assess challenges and opportunities that influence Chronic Neuropathic Pain R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each

project along with key milestones

Devise Chronic Neuropathic Pain in licensing and out licensing strategies by identifying prospective partners with progressing projects for Chronic Neuropathic Pain to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

## Contents

### 1. REPORT INTRODUCTION

### 2. CHRONIC NEUROPATHIC PAIN

- 2.1. Chronic Neuropathic Pain Disease Overview
- 2.2. Chronic Neuropathic Pain History
- 2.3. Chronic Neuropathic Pain Symptoms
- 2.4. Chronic Neuropathic Pain Causes
- 2.5. Chronic Neuropathic Pain Pathophysiology
- 2.6. Chronic Neuropathic Pain Diagnosis
  - 2.6.1. Diagnostic Guidelines

### 3. CHRONIC NEUROPATHIC PAIN CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

### 4. CHRONIC NEUROPATHIC PAIN - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
  - 4.1.1. Chronic Neuropathic Pain companies collaborations, Licensing, Acquisition –Deal Value Trends
    - 4.1.1.1. Assessment Summary
  - 4.1.2. Chronic Neuropathic Pain Collaboration Deals
    - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    - 4.1.2.2. Chronic Neuropathic Pain Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
  - 4.2.1. Assessment by Phase of Development
  - 4.2.2. Assessment by Product Type (Mono / Combination)
    - 4.2.2.1. Assessment by Stage and Product Type
  - 4.2.3. Assessment by Route of Administration
    - 4.2.3.1. Assessment by Stage and Route of Administration
  - 4.2.4. Assessment by Molecule Type
    - 4.2.4.1. Assessment by Stage and Molecule Type
  - 4.2.5. Assessment by MOA
    - 4.2.5.1. Assessment by Stage and MOA

## **5. CHRONIC NEUROPATHIC PAIN PIPELINE THERAPEUTICS**

- 5.1. Late Stage Products (Phase-III)
  - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
  - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
  - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
  - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

## **6. CHRONIC NEUROPATHIC PAIN -PRODUCTS ANALYSIS**

- 6.1. Product Profiles
  - 6.1.1. AP-325- Algiax Pharmaceuticals
    - 6.1.1.1. Product Description
      - 6.1.1.1.1. Product Overview
      - 6.1.1.1.2. Mechanism of Action
    - 6.1.1.2. Research and Development
      - 6.1.1.2.1. Clinical Studies
        - 6.1.1.2.1.1. Detailed Study Description
        - 6.1.1.2.1.2. Study Results
        - 6.1.1.2.1.3. Clinical Trials: Tabular View
    - 6.1.1.3. Product Development Activities
      - 6.1.1.3.1. Tabulated Product Summary
        - 6.1.1.3.1.1. General Description Table
  - 6.1.2. Desmetramadol- Syntrix Biosystems
    - 6.1.2.1. Product Description
      - 6.1.2.1.1. Product Overview
      - 6.1.2.1.2. Mechanism of Action
    - 6.1.2.2. Research and Development
      - 6.1.2.2.1. Clinical Studies
        - 6.1.2.2.1.1. Detailed Study Description
        - 6.1.2.2.1.2. Study Results
        - 6.1.2.2.1.3. Clinical Trials: Tabular View
    - 6.1.2.3. Product Development Activities
      - 6.1.2.3.1. Tabulated Product Summary
        - 6.1.2.3.1.1. General Description Table

### 6.1.3. CNTX 2022- Centrexion Therapeutics

#### 6.1.3.1. Product Description

##### 6.1.3.1.1. Product Overview

##### 6.1.3.1.2. Mechanism of Action

#### 6.1.3.2. Research and Development

##### 6.1.3.2.1. Clinical Studies

###### 6.1.3.2.1.1. Detailed Study Description

###### 6.1.3.2.1.2. Study Results

###### 6.1.3.2.1.3. Clinical Trials: Tabular View

#### 6.1.3.3. Product Development Activities

##### 6.1.3.3.1. Tabulated Product Summary

###### 6.1.3.3.1.1. General Description Table

To be continued in the report.....

## **7. RECENT TECHNOLOGIES**

## **8. CHRONIC NEUROPATHIC PAIN KEY COMPANIES**

8.1. GlaxoSmithKline

8.2. Chiesi Farmaceutici

8.3. Novartis

8.4. Esteve

8.5. Neuromed Pharmaceuticals

8.6. Glenmark Pharmaceuticals

8.7. Diamyd Medical

8.8. Amgen

8.9. AstraZeneca

8.10. Tools4Patient

8.11. AstraZeneca

8.12. Newron Pharmaceuticals

8.13. Avigen

8.14. Grunenthal

8.15. Immune Pharmaceuticals

8.16. Algiax Pharmaceuticals

## **9. CHRONIC NEUROPATHIC PAIN KEY PRODUCTS**

9.1. 4030W92

9.2. Indantadol

- 9.3. Olodanrigan
- 9.4. E 52862
- 9.5. Z 160
- 9.6. GRC 17536
- 9.7. NP 2
- 9.8. Fulranumab
- 9.9. AZD 6088
- 9.10. T4P 1001
- 9.11. AZD 2066
- 9.12. Ralfinamide
- 9.13. Research programme: neuropathic pain and drug abuse therapies
- 9.14. Axomadol
- 9.15. Amitriptyline/ketamine
- 9.16. AP-325
- 9.17. Desmetramadol

## **10. DORMANT AND DISCONTINUED PRODUCTS**

- 10.1. Dormant Products
  - 10.1.1. Reasons for being dormant
- 10.2. Discontinued Products
  - 10.2.1. Reasons for the discontinuation

## **11. CHRONIC NEUROPATHIC PAIN - UNMET NEEDS**

## **12. CHRONIC NEUROPATHIC PAIN - FUTURE PERSPECTIVES**

## **13. APPENDIX**

## **14. REPORT METHODOLOGY**

- 14.1. Secondary Research
- 14.2. Expert Panel Validation



## List Of Tables

### LIST OF TABLES

- Table 1. Chronic Neuropathic Pain Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Chronic Neuropathic Pain Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

## List Of Figures

### LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Chronic Neuropathic Pain companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Chronic Neuropathic Pain Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

### KEY COMPANIES

GlaxoSmithKline  
Chiesi Farmaceutici  
Novartis  
Esteve

Neuromed Pharmaceuticals  
Glenmark Pharmaceuticals  
Diamyd Medical  
Amgen  
AstraZeneca  
Tools4Patient  
AstraZeneca  
Newron Pharmaceuticals  
Avigen  
Grunenthal  
Immune Pharmaceuticals

## I would like to order

Product name: Chronic Neuropathic Pain (CNP) - Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/C7F29E6AC38EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7F29E6AC38EN.html>